Member Info for David1951c

Five sells of about 500k shares and SP drops 6%. It happens with many small companies. Pricing methodology on AIM stinks!

Thanks for comments tomphys and the key matter of FDA. I am not a large investor but getting to 25k shares is my objective by buying on these dips when cash is available. Investors at 116p placing would be more aware of the position than me but it does seem a buying opportunity with risk but upside seems more reward than risk given the progress. I am doing the same with DEST.

How can anyone outside the company know when the next news will arrive? The six months results to 30 June 2021 should be announced in September and of course other news could arrive sooner but who knows? The drop from the June placing is disappointing but it seems much of this sector of market (and AIM generally) is annoyingly on a downward trend. Also SP is much higher than at 2019 and 2020 placings.
Angle are advancing along numerous avenues (as set out and funded in the last placing) and with progress SP should rise during H2 assuming news continues to be good. On AIM it is so frustrating that SPs fall on such small volumes and if you are confident in the company, just keep patient.

ONC are not the greatest at providing updates (but not as bad as SNG) but with so much on the go I look for a RNS most mornings. The last full update included "The ImmunoINSIGHTS pipeline of qualified commercial opportunities has continued to grow throughout FY21 and currently stands at more than 160. A number of these opportunities are in late stage legal documentation and, as a consequence, the Company expects to sign these new contracts in Q1 FY22."
This means by 31 August. So 2 weeks to go!

Usually AGMs are more of a formality unless there are dissenting shareholders. New would usually come by RNS. Quarterly updates started last month so one question for me is whether some news might not be announced until the next Qtrly update. Hopefully with so much going on there will actually be a stream of news. EQT previously said about the fund raise "Finally, EQTEC will expand its engineering capacity and business development capabilities to pursue more opportunities more rapidly." If this is achieved then news flow should be monthly!
Some sells today but one for 300k was actually a buy. Price 1.369 seems OK as I feel SP has already bottomed.

Last year shareholders were told that the Board would improve communication. At first it happened but now I am not sure communication is effective.
This was my first small biotech investment nearly four years ago as then I felt there was huge potential in a really positive looking pipeline. After those four years (and even allowing for consolidation I am in profit) I am now more inclined to bail out because of doubts the wonder products will come about.
Half year report should be due in early September so I may wait until then. It would be great to see an update on where we are before then but comms are not so good again.

As an investor in small bio tech companies with lots of potential (high reward / risk) the most important factor is funding. At the last raise FUM said there would be enough funding to Q1 2022. The key question is whether commercialisation and collaboration deals will provide the funds to make another raise less likely next year. There is much happening and I took the view that funding if required would be at a higher price on the basis SP will rise on a stream of positive news. So bought 10k more shares today @38.90 - mind you it is shown as a sell on here.

Last RNS on patents was nearly six months ago so news should be due on Europe and Australia. Not sure there is much info on progress or timescales for USA though. A six month update in August for H1 would be welcome.

Significant increase in holding to 20m shares. Hard to know if they will increase further. Equally important is the timing as perhaps they see news coming sooner rather than later and want a bigger slice before SP rises on trial outcomes.

Last year the June update was on 6 August so there might be one this week. Last news was positive and hopefully continues with increased revenue including new sites.

The closing comment is significant "Second, reduction in S. aureus nasal colonization is associated with decreased numbers of all staphylococcal infections". Inclusion of word "all" demonstrates an even better outcome.
With work on-going preparatory work for phase 3s in both M3 and XF73 the rest of 2021 and especially 2022 should be highly significant in the progress for both. Probably the confirmation of phase 3 protocols and announcement of partnerships for the P3s to happen are the next key milestones. Looking forward to more II interest as this all moves forward.

Positive update and increases the potential. RBW could be more dynamic in their communication. Instead of releasing PEA to the market in due course, it would be much more informative to give an expected date. If RBW are ahead of competitors it would be even better to have clearer timelines for all steps to production as more likely to attract additional investors. Burundi news is hopefully not far away as GB has been there about a month.

Latest small 2,500 buy 114p also shown as a sell. Even if system judges it a sell by virtue of the price it could be shown as a negative sell! Misleading for investors seeing a sea of red when it is not.

Thanks for the nudge on patents. N4P update on 11 February is copied below. More news due in September - December hopefully.

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.
Having received the notification the next steps prior to formal grant will require UQ to confirm the particulars and translations with the EPO prior to publication of the grant after which the Patent will be validated on a country by country basis throughout Europe as determined by UQ and the Company. This process, resulting in the full grant of the Patent in each chosen territory, should take six to eight months.

Thank goodness ED has gone. In the last two shareholder updates he was unimpressive and the poor skills almost convinced me to sell even at a loss. My 11 year old grandson is a better public speaker!
Bringing in an experienced CEO can only help with progress and give more confidence on delivery which has been woeful even allowing for the pandemic. Rebuilding trust of shareholders is critical and possibly more II involvement through new CEO's connections. Hopefully costs will not be increased materially.

Hi Trek,
Thanks for words of wisdom. I am not a trader but rebalance where I can. I am overweight in Avacta because I bought quite a lot over three years ago and have a large free carry. Not quite the same with SNG but I had some at the bottom so well up. In both cases I am a long term holder (if 3+years counts as LTH) and happy to see out both in next couple of years. ONC is third in my bio holdings and again I will hold for medium term. Have numerous others (too many) but my other favourite in sector is Destiny where I hope to get to 80k shortly. Rocky SP in 2021 but I have great hopes for P3s in 2022.
On mining I already have some CCZ and quite a few others including RBW, MKA, ARC, EEE, GLR and BMV. Spread is to replicate a portfolio without being too overweight in any one miner as very volatile. Also have HE1 where you post regularly, from 8p days. Again I don't want too much in one share but have quite a lot in the basket.
Interesting times on AIM in 2021 after a mega 2020 and although SP movements on small volumes are frustrating and hard to understand, it is very difficult to see which are the likely winners. My approach is to try and buy in at a low price so there is plenty of choice right now!

As an investor (rather than a miner) for some years with a number of mining stocks, the latest results in today's RNS are fairly ordinary in isolation so I am not surprised at SP drop. As part of the Big One picture the results are incremental. Further assays are to follow with results in a few weeks - why can't the company give a more specific timeline rather than a vague one? What are the target dates for further assays to be completed and results released? CCZ could be more dynamic in shareholder updates.

Trek,
I was away for a few days and you write an investment case for PIs!! Obviously ONC is heading steadily in one direction even if the SP doesn't always follow suit. I did buy a few k more but don't have spare cash without selling others and I don't wan to do that at present. I have bigger holdings in Avacta and SNG which if they regain some lost ground, I will rebalance here. Without some more II involvement the SP may continue to be volatile but this remains a medium to long term hold for me.
I still wonder about a bid from Roche or other major but may be wishful thinking. With more news by 31 August we should get comfortably over £2 again but will it be sustained?

So how close are BMV to actual production? I cannot find any clear dates or timetable which would entice me to buy more shares at present. I got to nearly 1m and stopped because of lessening faith in BoD to deliver at pace. Why should a prospectus take up to six months when so much work was done on the last one a few years ago?

Decline in SP has hardly been a selling frenzy based on the daily number of trades and amounts. It has been fairly slow but steady selling which on AIM means a disproportionate SP drop. I was hoping for more II interest as the number of major shareholders is not as material as it could and should be. The fundamentals are good but ONC need to get more deals completed and keep up a regular news flow to up and sustain a higher SP. It has been an opportunity to add in expectation ONC will get more shareholder value from the assets and pipeline than is currently the case.